ReviewPrzeglad menopauzalny = Menopause review2024
The use of hyaluronic acid fillers in patients with autoimmune endocrinopathies; in particular, women with Hashimoto's disease - hints for aesthetic doctors.
Review in Przeglad menopauzalny = Menopause review, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase of the incidence of autoimmune diseases and, at the same time, a significant surge in the number of regenerative/anti-aging medicine treatments carried out, raises the need to systematise the current knowledge on the safety of the use of hyaluronic acid fillers in patients with autoimmune diseases and to frame management guidelines for aesthetic doctors. One of the most prevalent autoimmune diseases is chronic lymphocytic thyroiditis, so-called Hashimoto's disease, which affects one in every 5-10 women who visit a regenerative medicine doctor. Women in the perimenopausal and menopausal period, aged 40-54 years, were the single largest target group for aesthetic treatments. At the same time, Hashimoto's disease, similarly to other autoimmune disorders, constitutes a contraindication to most treatments with hyaluronic acid fillers and biostimulators. Due to the dysfunction of the immune system in this group of patients, there is a higher risk of adverse side effects, especially those of immunological nature. Based on the available literature, the incidence of adverse reactions after the use of hyaluronic acid-based fillers amounts to 0.01-1% and is undoubtedly underestimated. The most typical one is recurrent oedema and granulomas. The following paper reviews the existing literature on the safety of hyaluronic acid fillers in patients with autoimmune endocrinopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.